U.S. markets close in 5 hours 33 minutes
  • S&P 500

    3,714.18
    +20.95 (+0.57%)
     
  • Dow 30

    29,619.77
    +29.36 (+0.10%)
     
  • Nasdaq

    11,015.67
    +147.74 (+1.36%)
     
  • Russell 2000

    1,688.67
    +9.08 (+0.54%)
     
  • Crude Oil

    80.15
    +1.41 (+1.79%)
     
  • Gold

    1,654.10
    -1.50 (-0.09%)
     
  • Silver

    19.00
    +0.09 (+0.48%)
     
  • EUR/USD

    0.9677
    -0.0011 (-0.12%)
     
  • 10-Yr Bond

    3.7750
    +0.0780 (+2.11%)
     
  • GBP/USD

    1.0829
    -0.0027 (-0.25%)
     
  • USD/JPY

    144.1780
    +0.8580 (+0.60%)
     
  • BTC-USD

    19,230.70
    +319.65 (+1.69%)
     
  • CMC Crypto 200

    441.28
    +8.18 (+1.89%)
     
  • FTSE 100

    7,018.87
    +0.27 (+0.00%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

U.S. FDA panel votes for Amylyx's ALS drug

Sept 7 (Reuters) - Amylyx Pharmaceuticals Inc's drug for amyotrophic lateral sclerosis (ALS) won the support of external advisers to the U.S. Food and Drug Administration on Wednesday.

The FDA panel voted 7 to 2 in favor of the oral drug, AMX0035, citing the unmet need for more treatments against the fatal neurodegenerative condition commonly known as Lou Gehrig's disease. (Reporting by Leroy Leo and Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)